- Home
- GORV vs GDTC Comparison
GORV vs GDTC Comparison
Compare GORV & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- GDTC
- Stock Information
- Founded
- GORV 1976
- GDTC 2018
- Country
- GORV United States
- GDTC Singapore
- Employees
- GORV N/A
- GDTC N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- GDTC Health Care
- Exchange
- GORV Nasdaq
- GDTC Nasdaq
- Market Cap
- GORV 31.8M
- GDTC 28.0M
- IPO Year
- GORV 2015
- GDTC 2023
- Fundamental
- Price
- GORV $0.26
- GDTC $2.04
- Analyst Decision
- GORV Hold
- GDTC Buy
- Analyst Count
- GORV 2
- GDTC 1
- Target Price
- GORV $2.00
- GDTC $5.00
- AVG Volume (30 Days)
- GORV 24.1M
- GDTC 9.2K
- Earning Date
- GORV 05-15-2025
- GDTC 01-01-0001
- Dividend Yield
- GORV N/A
- GDTC N/A
- EPS Growth
- GORV N/A
- GDTC N/A
- EPS
- GORV N/A
- GDTC N/A
- Revenue
- GORV $767,257,000.00
- GDTC $368,838.00
- Revenue This Year
- GORV $15.65
- GDTC $5.37
- Revenue Next Year
- GORV $20.54
- GDTC N/A
- P/E Ratio
- GORV N/A
- GDTC N/A
- Revenue Growth
- GORV N/A
- GDTC N/A
- 52 Week Low
- GORV $0.13
- GDTC $1.20
- 52 Week High
- GORV $3.75
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- GORV 51.90
- GDTC 38.29
- Support Level
- GORV $0.25
- GDTC $2.00
- Resistance Level
- GORV $0.29
- GDTC $2.45
- Average True Range (ATR)
- GORV 0.06
- GDTC 0.12
- MACD
- GORV 0.01
- GDTC -0.02
- Stochastic Oscillator
- GORV 34.45
- GDTC 4.46
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.